🔎 Trials Near Me

Почетна › Hronična limfocitna leukemija › Њујорк › New York City

Kliničke studije za Hronična limfocitna leukemija u gradu New York City, NY

20 studija za Hronična limfocitna leukemija traži učesnike na lokacijama u gradu New York City i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Тражи се учесникФаза 3
  • Memorial Sloan Kettering Cancer Center, New York
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04269902

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Тражи се учесникФаза 3
  • Memorial Sloan Kettering Cancer Center Mskcc, New York
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06846671

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Тражи се учесникФаза 4
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07218341

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Тражи се учесникФаза 3
  • Mount Sinai Hospital, New York
Узраст 65 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07321652

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Тражи се учесникФаза 1/2
  • Research Site, New York
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06564038

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Тражи се учесникФаза 3
  • Memorial Sloan Kettering Cancer Center Mskcc, New York
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06943872

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Тражи се учесникФаза 3
  • David H. Koch Center for Cancer Care, New York
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07648264

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Тражи се учесникФаза 2
  • NYP/Weill Cornell Medical Center, New York
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT07061951

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Тражи се учесникФаза 1/2
  • Columbia University Medical Center, New York
  • Weill Cornell Medical College Newyork Presbyterian Hospital, New York
  • Memorial Sloan Kettering Cancer Center Mskcc, New York
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT05006716

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Тражи се учесникФаза 1/2
  • Research Site, New York
  • Research Site, New York
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT06542250

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Тражи се учесникФаза 3
  • Columbia University Medical Center, New York
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Тражи се учесникФаза 3
  • Columbia University Medical Center, New York
  • Weill Cornell Medical College Newyork Presbyterian Hospital, New York
  • Memorial Sloan Kettering Cancer Center Mskcc, New York
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06973187

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Тражи се учесникФаза 1
  • Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Узраст 18 и старији · Оба пола · Ажурирано 8. 9. 2026. · NCT03666000

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

Тражи се учесникФаза 2
  • Memorial Sloan Kettering Cancer Center, New York
Узраст 18 и старији · Оба пола · Ажурирано 11. 8. 2026. · NCT06849713

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Тражи се учесникФаза 3
  • Icahn School of Medicine at Mount Sinai /ID# 266328, New York
Узраст 18 и старији · Оба пола · Ажурирано 9. 4. 2026. · NCT06428019

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Тражи се учесникФаза 2
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT07218510

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Тражи се учесникФаза 4
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Тражи се учесникФаза 4
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876662

Study of SGR-1505 in Mature B-Cell Neoplasms

Тражи се учесникФаза 1
  • Weill Cornell, New York
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT05544019

Studije za Hronična limfocitna leukemija u drugim gradovima

Ostale studije u gradu New York City

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.